Upsher Launches K-Dur Generic With Exclusivity; FTC Hearing In December
Executive Summary
Upsher-Smith expects to be the only generic competitor to Schering-Plough's K-Dur until March 1, 2002.
You may also be interested in...
FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering
Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said
FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering
Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said
Andrx Plans Diltiazem ANDA Amendment In May; Biovail Delists Tiazac Patent
Andrx plans to amend its ANDA for a generic version of Biovail's Tiazac in May following a request by FDA for additional data, the company said